Sign in
CompletedNo phase

Evaluation of the Predictive Impact of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium

Key facts

Who runs it
Ankara University
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
137 people enrolled
Started
27 Sept 2023
Ended
6 Nov 2024
Type of study
Observational
Treatments tested
  • Perioperative Assessment
Record updated
3 April 2026

Who can take part

Age
18 years to 120 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adult patients (≥18 years) undergoing elective surgery under anesthesia
  • Patients able to provide informed consent
  • Patients with sufficient cognitive function to complete cognitive assessments
  • Patients who agreed to participate in follow-up evaluations

Who cannot take part

  • Patients undergoing emergency surgery
  • Patients with a history of neurological or psychiatric disorders affecting cognitive function
  • Patients with diagnosed dementia or severe cognitive impairment
  • Patients with inability to complete cognitive tests (e.g., severe visual, hearing, or language impairment)
  • Patients with alcohol or substance abuse
  • Patients with missing baseline cognitive assessment
  • Patients who refused participation or were lost to follow-up

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Postoperative cognitive disorders, including postoperative cognitive dysfunction (POCD) and postoperative delirium (POD), are common complications following surgery and anesthesia, particularly in vulnerable patient populations. These conditions are associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Early identification of patients at risk remains challenging, and reliable biomarkers are needed to improve perioperative risk stratification.

Read full original descriptionShow less

S100B protein has been proposed as a biomarker of neuronal injury and blood-brain barrier dysfunction. In addition, genetic variations in the S100B gene may influence individual susceptibility to postoperative cognitive impairment.

The aim of this prospective cohort study is to evaluate the association between perioperative serum S100B levels, S100B gene polymorphisms, and postoperative cognitive disorders. Furthermore, the predictive value of perioperative changes in S100B levels for postoperative cognitive dysfunction and delirium will be investigated.

The group in the trial

  • Surgical Patients

    Patients undergoing surgery who were prospectively followed for postoperative delirium and postoperative cognitive dysfunction with serial cognitive assessments, serum S100B measurements, and S100B gene polymorphism analyses.

    Treatment: Perioperative Assessment

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Investigation of the Predictive Effect of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium in Patients Undergoing Surgery With Bispectral Index Monitoring
Record updated
3 April 2026